Gene · 51185
NIH grants1,407
NIH grants whose papers are about the gene, through NIH's grant-paper links.
221 to 240 of 1,407
Download this page as JSON| Grant | Title | CRBN papers | Newest fiscal year |
|---|---|---|---|
| R01CA258327 | Imaging and manipulating oncoprotein phase separation and compartmentalization | 1 | 2025 |
| R01CA259273 | Defining epigenetic mechanisms in NPM1c mutant leukemia | 1 | 2025 |
| R01CA260137 | Targeting a phosphatidylserine/TAM receptor/PD-L1 axis as a vulnerability in cancer | 1 | 2025 |
| R01CA260900 | STING-dependent Intestinal Regeneration upon Radiation Injury | 1 | 2025 |
| R01CA262530 | Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers | 1 | 2025 |
| R01CA262623 | Systematic Characterization of Small Nucleolar RNAs in Cancer | 1 | 2025 |
| R01CA265050 | New Therapuetics for Pancreatic Cancer | 1 | 2025 |
| R01CA266027 | Preventing adaptive drug resistance through Mediator kinase inhibition | 1 | 2025 |
| R01CA266057 | Novel Small-Molecule Probes Targeting Oncogenic Fusion MLL in Pediatric Leukemia | 1 | 2025 |
| R01CA269661 | Exploring novel therapeutic strategies for combinatory therapy to treat renal clear cell carcinomas | 1 | 2025 |
| R01CA269919 | Comprehensive identification of germline-somatic interactions | 1 | 2025 |
| R01CA272426 | preclinical optimization of BCMA directed T cell therapy | 1 | 2025 |
| R01CA272645 | Design of the First Mdm2 Targeting PROTACs for treatment of p53 Mutant or Deficient Cancers | 1 | 2025 |
| R01CA273095 | Identification and characterization of chemical probes for interrogation of the NEK family of kinases in cancer | 1 | 2025 |
| R01CA273226 | Targeting PKR-Bcl2 Signaling to Overcome Paclitaxel Resistance in Ovarian Cancer | 1 | 2025 |
| R01CA282483 | Developing novel therapy to improve outcomes in MCL | 1 | 2025 |
| R01CA284593 | Myeloid cell-selective, oligonucleotide-based STAT3 inhibition combined with total marrow and lymphoid irradiation for immunotherapy of acute myeloid leukemia | 1 | 2025 |
| R01CA289881 | Targetable epigenetic modifiers that promote neuroblastoma malignancy and plasticity | 1 | 2025 |
| R01DA038446 | 5-HT2 Receptor Allosterism in Cocaine Use Disorder | 1 | 2025 |
| R01DE030480 | Multi-Tissue Craniofacial Engineering using 3D-BMP9-Notch-Synergized Graphene Citrate Composite Scaffolds | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51185/grants?page=12